FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4360616104> ?p ?o ?g. }

• W4360616104 endingPage "154782" @default.
• W4360616104 startingPage "154782" @default.
• W4360616104 abstract "Gout is a crystal related arthropathy caused by monosodium urate deposition. At present, the identification of appropriate treatments and new drugs to reduce serum uric acid levels and gout risk is a major research area. Theaflavins are naturally occurring compounds characterized by a benzodiazepine skeleton. The significant benefits of theaflavins have been well documented. A large number of studies have been carried out and excellent anti-gout results have been achieved in recent years. A comprehensive analysis of the mechanism of the anti-gout effect of theaflavins is presented through a literature review and network pharmacology prediction, and strategies for increasing the bioavailability of theaflavins are summarized. In this review, the active components and pharmacological mechanisms of theaflavins in the treatment of gout were summarized, and the relationship between theaflavins and gout, the relevant components, and the potential mechanisms of anti-gout action were clarified by reviewing the literature on the anti-gout effects of theaflavins and network pharmacology. Theaflavins exert anti-gout effects by down regulating the gene and protein expression of glucose transporter 9 (GLUT9) and uric acid transporter 1 (URAT1), while upregulating the mRNA expression levels of organic anion transporter 1 (OAT1), organic cation transporter N1 (OCTN1), organic cation transporters 1/2 (Oct1/2), and organic anion transporter 2 (OAT2). Network pharmacology prediction indicate that theaflavins can regulate the AGE-RAGE and cancer signaling pathways through ATP-binding cassette subfamily B member 1 (ABCB1), recombinant mitogen activated protein kinase 14 (MAPK14), telomerase reverse tranase (TERT), signal transducer and activator of transcription 1 (STAT1), matrix metalloproteinase 2 (MMP2), B-cell lymphoma-2 (BCL2), and matrix metalloproteinase 14 (MMP14) targets for anti-gout effects. This review presents the mechanisms of anti-gout action of theaflavins and strategies for improving the bioavailability of theaflavins, as well as providing research strategies for anti-gout treatment measures and the development of novel anti-gout drugs." @default.
• W4360616104 created "2023-03-24" @default.
• W4360616104 creator A5009667073 @default.
• W4360616104 creator A5016940098 @default.
• W4360616104 creator A5024245709 @default.
• W4360616104 creator A5024701679 @default.
• W4360616104 creator A5026127718 @default.
• W4360616104 creator A5032739196 @default.
• W4360616104 creator A5066105618 @default.
• W4360616104 creator A5088888083 @default.
• W4360616104 date "2023-06-01" @default.
• W4360616104 modified "2023-10-15" @default.
• W4360616104 title "Mechanisms of theaflavins against gout and strategies for improving the bioavailability" @default.
• W4360616104 cites W1191933023 @default.
• W4360616104 cites W1993347615 @default.
• W4360616104 cites W1994639012 @default.
• W4360616104 cites W1998117581 @default.
• W4360616104 cites W2008275526 @default.
• W4360616104 cites W2028582197 @default.
• W4360616104 cites W2029207036 @default.
• W4360616104 cites W2051925512 @default.
• W4360616104 cites W2056617927 @default.
• W4360616104 cites W2073263307 @default.
• W4360616104 cites W2104458949 @default.
• W4360616104 cites W2150669985 @default.
• W4360616104 cites W2168938595 @default.
• W4360616104 cites W2596305762 @default.
• W4360616104 cites W2621034172 @default.
• W4360616104 cites W2622666676 @default.
• W4360616104 cites W2734270485 @default.
• W4360616104 cites W2743905759 @default.
• W4360616104 cites W2758749736 @default.
• W4360616104 cites W2766821699 @default.
• W4360616104 cites W2786838443 @default.
• W4360616104 cites W2797282715 @default.
• W4360616104 cites W2799785234 @default.
• W4360616104 cites W2892735522 @default.
• W4360616104 cites W2902714238 @default.
• W4360616104 cites W2906157226 @default.
• W4360616104 cites W2908011662 @default.
• W4360616104 cites W2924817651 @default.
• W4360616104 cites W2944076262 @default.
• W4360616104 cites W2948772025 @default.
• W4360616104 cites W3004438077 @default.
• W4360616104 cites W3015941204 @default.
• W4360616104 cites W3034280373 @default.
• W4360616104 cites W3037829679 @default.
• W4360616104 cites W3085874327 @default.
• W4360616104 cites W3119143490 @default.
• W4360616104 cites W3124677519 @default.
• W4360616104 cites W3134269422 @default.
• W4360616104 cites W3157014149 @default.
• W4360616104 cites W3174798679 @default.
• W4360616104 cites W4210302532 @default.
• W4360616104 cites W4210648715 @default.
• W4360616104 cites W4214844457 @default.
• W4360616104 cites W4220914134 @default.
• W4360616104 cites W4225117547 @default.
• W4360616104 cites W4231686634 @default.
• W4360616104 cites W4239736175 @default.
• W4360616104 cites W4248403572 @default.
• W4360616104 cites W4281697714 @default.
• W4360616104 cites W4282937726 @default.
• W4360616104 cites W4283325516 @default.
• W4360616104 doi "https://doi.org/10.1016/j.phymed.2023.154782" @default.
• W4360616104 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36990009" @default.
• W4360616104 hasPublicationYear "2023" @default.
• W4360616104 type Work @default.
• W4360616104 citedByCount "3" @default.
• W4360616104 countsByYear W43606161042023 @default.
• W4360616104 crossrefType "journal-article" @default.
• W4360616104 hasAuthorship W4360616104A5009667073 @default.
• W4360616104 hasAuthorship W4360616104A5016940098 @default.
• W4360616104 hasAuthorship W4360616104A5024245709 @default.
• W4360616104 hasAuthorship W4360616104A5024701679 @default.
• W4360616104 hasAuthorship W4360616104A5026127718 @default.
• W4360616104 hasAuthorship W4360616104A5032739196 @default.
• W4360616104 hasAuthorship W4360616104A5066105618 @default.
• W4360616104 hasAuthorship W4360616104A5088888083 @default.
• W4360616104 hasConcept C104317684 @default.
• W4360616104 hasConcept C123584848 @default.
• W4360616104 hasConcept C126322002 @default.
• W4360616104 hasConcept C134018914 @default.
• W4360616104 hasConcept C149011108 @default.
• W4360616104 hasConcept C181389837 @default.
• W4360616104 hasConcept C185592680 @default.
• W4360616104 hasConcept C2779721657 @default.
• W4360616104 hasConcept C2779881121 @default.
• W4360616104 hasConcept C2780261098 @default.
• W4360616104 hasConcept C2780274859 @default.
• W4360616104 hasConcept C2780402116 @default.
• W4360616104 hasConcept C55493867 @default.
• W4360616104 hasConcept C71924100 @default.
• W4360616104 hasConcept C98274493 @default.
• W4360616104 hasConceptScore W4360616104C104317684 @default.
• W4360616104 hasConceptScore W4360616104C123584848 @default.
• W4360616104 hasConceptScore W4360616104C126322002 @default.
• W4360616104 hasConceptScore W4360616104C134018914 @default.

• next